Home > Category > Signaling Pathways > Protein Tyrosine Kinase/RTK > c-Fms > Sotuletinib (BLZ945)

Sotuletinib (BLZ945)

ChemLeader 98+%

Catalog No：CL2550 CAS No.：953769-46-5 MDLNo： Formula：C20H22N4O3S MW：398.48

Collect Share

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Chemical safety data sheet(MSDS)

Download MSDS

Inquiry Add To Cart

Product Overview
Related documents
Product details
Related literature

Product Overview

Product Name	Sotuletinib (BLZ945)
CAS	953769-46-5
Formula	C20H22N4O3S
MW	398.48
Appearance	Off-white to light brown powder
Storage condition	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

Product details

Sotuletinib (formerly BLZ945; BLZ-945) is a novel, potent, selective, orally bioactive, and brain-penetrant CSF-1R (colony stimulating factor 1 receptor) inhibitor with potential antitumor activity. It exhibits 1000-fold higher selectivity against its closest receptor tyrosine kinase homologs and inhibits CSF-1R with an IC50 of 1 nM. Glioma-bearing mice demonstrate high in vivo antitumor efficaciousness of BLZ945. Sotuletinib was designated as an orphan drug by the US FDA in August 2022 in order to treat patients suffering from Amyotrophic Lateral Sclerosis (ALS), a progressive neurological disorder that affects nerve cells in the brain and spinal cord and results in loss of motor control.

Related literature

Sorry, there is no relevant literature

Sorry, no related items

History

CL2550

Sotuletinib (BLZ945)

953769-46-5 98+%